Switch to Quad Pill Maintained HIV Suppression (CME/CE)

Switch to Quad Pill Maintained HIV Suppression (CME/CE)

HIV patients can be successfully switched from a twice-daily integrase inhibitor regimen to a once-daily, single-tablet regimen without loss of viral suppression, researchers reported here.

At 48 weeks, all 46 patients who switched from a raltegravir-based (Isentress) regimen to the four-drug, elvitegravir-cobicistat-tenofovir-emtricitabine (Stribild) pill were able to maintain undetectable viral load using the 50 copies/ml assay, said Gordon Crofoot, MD, a Houston-based HIV researcher in private practice.